NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES

1 - 60 . (canceled)

61 . A method of increasing minute ventilation in a subject in need thereof, the method comprising administering to the subject an effective amount of at least one compound of formula (I):

wherein

R 1 and R 2 are independently alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, phenyl, substituted phenyl, phenylalkyl, substituted phenylalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, heteroaryl or substituted heteroaryl; or R 1 and R 2 combine as to form a biradical selected from the group consisting of 3-hydroxy-pentane-1,5-diyl, 6-hydroxy-cycloheptane-1,4-diyl, propane-1,3-diyl, butane-1,4-diyl and pentane-1,5-diyl;

R 3 is H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, —NR 1 R 2 , —C(O)OR 1 , acyl, or aryl;

R 4 is H, alkyl, or substituted alkyl;

R 5 is H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, —OR 1 , —NR 1 R 2 , —C(O)OR 1 , acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, or substituted heterocyclic; or R 3 and R 5 combine as to form a biradical selected from the group consisting of 3,6,9-trioxa-undecane-1,11-diyl and 3,6-dioxa-octane-1,8-diyl;

R 6 is H, alkyl, substituted alkyl or alkenyl;

X is a bond, O or NR 4 ; and,

Y is N, CR 6 or C; wherein:

if Y is N or CR 6 , then bond b 1 is nil and:

(i) Z is H, bond b 2 is a single bond, and A is CH; or,

(ii) Z is nil, bond b 2 is nil, and A is a single bond;

and,

if Y is C, then bond b 1 is a single bond, and:

(i) Z is CH 2 , bond b 2 is a single bond, and A is CH; or,

(ii) Z is CH, bond b 2 is a double bond, and A is C;

or a salt thereof.

62 . The method of claim 61 , wherein the compound of formula (I) is selected from the group consisting of:

N-(4,6-Bis-methylamino-[1,3,5]triazin-2-yl)-N,O-dimethyl-hydroxylamine,

N-(4,6-Bis-ethylamino-[1,3,5]triazin-2-yl)-N,O-dimethyl-hydroxylamine,

N-(4-Cyclopropylmethyl)-N-(6-n-propylamino)[1,3,5]triazin-2-yl)-N,O-dimethyl-hydroxylamine,

N-(4-Ethylamino)-N-(6-n-propylamino)-[1,3,5]triazin-2-yl)-N,O-dimethyl-hydroxylamine,

N-(Bis-4,6-(2-methylpropylamino))[1,3,5]triazin-2-yl)-N,O-dimethyl-hydroxylamine,

N-(Bis-4,6-(2,2-dimethylpropylamino))[1,3,5]triazin-2-yl)-N,O-dimethyl-hydroxylamine,

N-(Bis-4,6-(2,2-dimethylpropylamino))[1,3,5]triazin-2-yl)-N,O-dimethyl-hydroxylamine,

N-(4,6-Bis-n-propylamino-[1,3,5]triazin-2-yl)-N,O-dimethyl-hydroxylamine,

N-(4-(Methoxy(methyl)amino)-6-(n-propylamino)-1,3,5-triazin-2-yl)propionamide,

6-(Methoxy(methyl)amino)-N 2 -propyl-1,3,5-triazine-2,4-diamine,

6-[1,2]Oxazinan-2-yl-N,N′-dipropyl-[1,3,5]triazine-2,4-diamine,

N-(4,6-Bis-n-propylamino-[1,3,5]triazin-2-yl)-O-isopropyl-N-methyl-hydroxylamine,

O-Benzyl-N-(4,6-bis-n-propylamino-[1,3,5]triazin-2-yl)-N-ethyl-hydroxylamine,

6-((Benzyloxy)(isopropyl)amino)-N 2 ,N 4 -dipropyl-1,3,5-triazine-2,4-diamine,

N-(4,6-Bis-n-propylamino-[1,3,5]triazin-2-yl)-N-ethyl-O-isopropyl-hydroxylamine,

N-(4,6-Bis-n-propylamino-[1,3,5]triazin-2-yl)-O-isobutyl-N-methyl-hydroxylamine,

6-(Methyl(thiophen-2-ylmethoxy)amino)-N 2 ,N 4 -dipropyl-1,3,5-triazine-2,4-diamine,

N-(4,6-Bis-n-propylamino-[1,3,5]triazin-2-yl)-O-cyclopropylmethyl-N-methyl-hydroxylamine,

N-(4,6-Bis-n-propylamino-[1,3,5]triazin-2-yl)-O-ethyl-N-methyl-hydroxylamine,

N-(4,6-Bis-n-propylamino-[1,3,5]triazin-2-yl)-O-(2,2-difluoro-ethyl)-hydroxylamine,

4-N-(2-Dimethylaminoethyl)amino-6-N-(n-propyl)amino-[1,3,5]triazin-2-yl)-N,O-dimethyl-hydroxylamine,

4-N-(3-(1-N-Methylimidazol-2-yl)-propyl)-amino-6-N-(n-propyl)amino-[1,3,5]triazin-2-yl)-N,O-dimethyl-hydroxylamine,

4-N-(1-N-Methylimidazol-2-yl)-methylamino-6-N-(n-propyl)amino-[1,3,5]triazin-2-yl)-N,O-dimethyl-hydroxylamine,

4,6-Bis-(N-(2-dimethylaminoethyl)amino)-[1,3,5]triazin-2-yl)-N,O-dimethyl-hydroxylamine,

4,6-Bis-(N-(pyridin-4-yl-methyl)amino)-[1,3,5]triazin-2-yl)-N,O-dimethyl-hydroxylamine,

4,6-Bis-[N-(3-methoxy-n-propyl)amino]-[1,3,5]triazin-2-yl)-N,O-dimethyl-hydroxylamine,

4,6-Bis-[N-(tetrahydropyran-4-yl-methyl)amino]-[1,3,5]triazin-2-yl)-N,O-dimethyl-hydroxylamine,

N-(5,8,11-Trioxa-2,14,16,18,19-pentaazabicyclo[13.3.1]nonadeca-1(18),15(19),16(17)-trien-17-yl)-N,O-dimethylhydroxylamine,

2,6-Bis-(N-n-propylamino)-[1,3]pyrimidin-4-yl)-N,O-dimethyl-hydroxylamine,

N-(4,6-Bis-n-propylamino-[1,3,5]triazin-2-yl)-N′,N′-dimethylhydrazine,

N-(4,6-Bis-n-propylamino-[1,3,5]triazin-2-yl)-N-methyl-N′-methylhydrazine,

2-(n-Propyl)amino-4-(i-propylamino-7-methyl-pyrrolidino[2,3-d]pyrimidine,

2-(n-Propyl)amino-4-dimethylamino-7-methyl-pyrrolidino[2,3-d]pyrimidine,

2-(n-Propyl)amino-4-methylamino-7-methyl-pyrrolidino[2,3-d]pyrimidine,

2-(n-Propyl)amino-4-(i-propyl)amino-7-i-propyl-pyrrolidino[2,3-d]pyrimidine,

2,4-Bis-(n-propyl)amino-7H-pyrrolidino[2,3-d]pyrimidine,

2-(n-Propyl)amino-4-(4-hydroxypiperidin-1-yl)-7-methyl-pyrrolidino[2,3-d]pyrimidine,

8-(7-Methyl-2-(n-propylamino)-pyrrolidino[2,3-d]pyrimidin-4-yl)-8-azabicyclo[3.2.1]octan-3-ol,

N-(2-Propylamino-7H-pyrrolo[2,3d]pyrimidin-4-yl)-N,O-dimethyl-hydroxylamine,

N-(2-(Propen-2-yl)amino-7-methyl-pyrrolo[2,3d]pyrimidin-4-yl)-N,O-dimethyl-hydroxylamine,

N-(2-(Propen-2-yl)amino-7-methyl-pyrrolo[2,3d]pyrimidin-4-yl)-O-methyl-hydroxylamine,

N-(2-n-Propylamino-7-methyl-pyrrolo[2,3d]pyrimidin-4-yl)-N,O-dimethyl-hydroxylamine,

N-(2-n-Propylamino-7-methyl-pyrrolo[2,3d]pyrimidin-4-yl)-O-methyl-hydroxylamine,

N-(2-n-Propylamino-7-methyl-pyrrolo[2,3d]pyrimidin-4-yl)-hydrazine,

N-Methyl-N-(2-n-propylamino-7-methyl-pyrrolo[2,3d]pyrimidin-4-yl)-hydrazine,

N,N-Dimethyl-N′-(2-n-propylamino-7-methyl-pyrrolo[2,3d]pyrimidin-4-yl)-hydrazine,

a salt thereof and mixtures thereof.

63 . The method of claim 62 , wherein the compound of formula (I) is N-(4,6-Bis-n-propylamino-[1,3,5]triazin-2-yl)-N,O-dimethyl-hydroxylamine, or a salt thereof.

64 . The method of claim 61 , wherein the pharmaceutical formulation is administered via intravenous infusion.

65 . The method of claim 64 , wherein the infusion dose of the pharmaceutical formulation is at least about 0.016 mg/kg/min of compound (I).

66 . The method of claim 65 , wherein the infusion dose of the pharmaceutical formulation is about 0.016 mg/kg/min of compound (I).

67 . The method of claim 61 , wherein the infusion dose of the pharmaceutical composition produce plasma concentrations of at least about 726 ng/mL of compound (I) in the subject.

68 . The method of claim 61 , wherein the subject is a mammal.

69 . The method of claim 68 , wherein the mammal is human.

70 . The method of claim 64 , wherein the infusion dose of the pharmaceutical formulation is about 0.012 mg/kg/min of compound (I).